Skip to main content

NCCN Adds Therapy Option to Pancreatic Adenocarcinoma Guidelines


The National Comprehensive Cancer Network (NCCN) has released their latest guidelines for the treatment of pancreatic adenocarcinoma, featuring a new therapy in the second-line setting.

An initial NCCN guideline update of 2017 for pancreatic adenocarcinoma included many changes to available surveillance, chemotherapy, and radiation options. The latest update adds another second-line therapy option for patients with a specific subset of disease.

As a second-line therapy for locally advanced, unresectable, metastatic pancreatic cancer with good performance status, pembrolizumab was added for disease previously treated with gemcitabine-based therapy or fluoropyrimidine-based therapy. The new indication for pembrolizumab applies only to microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors.


Related Content

Pancreatic Cancer Guidelines Do Not Cover Some Targetable Mutations

Pancreatic Cancer Resectability Criteria Could Be Simpler


Additionally, the guideline suggests considering microsatellite instability testing and/or mismatch repair testing on adenocarcinoma-confirmed or metastatic tumor tissue.—Zachary Bessette